Physiological Role
Apolipoprotein B is the obligatory structural protein of all atherogenic lipoproteins (cholesterol-carrying particles capable of depositing in arterial walls). LDL, VLDL, IDL and Lp(a) each carry a single ApoB molecule. This biological property makes ApoB measurement a direct count of the total number of circulating particles.
Cholesterol transport in the blood relies on these lipoproteins. Each atherogenic particle contains a core of cholesterol and triglycerides, wrapped in a phospholipid layer and stabilized by one ApoB molecule. Particle size and density vary: some are large and cholesterol-rich, others small and dense. Each carries exactly one ApoB.
When an LDL particle penetrates the arterial wall, the particle itself initiates the atherogenic process. Its retention in the intima (the inner arterial layer), followed by oxidation, triggers a local response. The more particles circulating, the higher the probability of retention. This is why particle count, measured by ApoB, is more informative than the amount of cholesterol they carry.
Reference Ranges
These reference ranges are derived from scientific literature and may differ from your laboratory's reference values.
Source : National Lipid Association, Expert Clinical Consensus on ApoB Management 2024-2025 (2024)
Biological Significance
An ApoB level in the optimal zone indicates a low number of circulating atherogenic particles. This profile is associated with low cumulative arterial wall exposure over the years.
Elevated values signal atherogenic particle traffic above the optimal target. This situation can coexist with LDL cholesterol considered normal. This discordance phenomenon frequently occurs in metabolic profiles marked by insulin resistance, where LDL particles are small, dense and numerous.
Very high values reflect a significant particle load. Cumulative exposure over time is the determining factor: Mendelian randomization data show that duration of exposure matters as much as instantaneous concentration.
ApoB gains informative value with repeated measurements. A single value indicates a snapshot. Two or three measurements spaced three to six months apart reveal a trajectory. This trajectory allows evaluation of lipid profile evolution and the effectiveness of nutritional adjustments.
Influencing Factors
Diet. Dietary fat quality directly influences ApoB particle count. High intake of saturated fats and dietary cholesterol tends to increase concentration. Soluble fibers and phytosterols help reduce intestinal cholesterol absorption.
Physical activity. Regular exercise, particularly moderate to vigorous aerobic activity, is associated with improved lipid profile. The effect operates through better insulin sensitivity and reduced small, dense LDL particle count.
Body composition. Visceral adiposity (fat surrounding abdominal organs) is a major factor in ApoB elevation. The accompanying insulin resistance promotes hepatic VLDL production, increasing the total number of atherogenic particles.
Insulin sensitivity. Insulin resistance is the primary driver of discordance between LDL cholesterol and ApoB. It causes overproduction of small, dense LDL particles, each carrying one ApoB molecule.
Genetics. Certain genetic variants influence ApoB concentration. Familial hypercholesterolemia, linked to LDL receptor mutations, manifests as elevated ApoB from childhood.
Age and sex. ApoB tends to increase with age. Before menopause, women show lower average values than men. This gap narrows after menopause.
Supplementation. Black garlic, included in the Singular formula, is the subject of studies evaluating its influence on lipid profile. Omega-3 (EPA+DHA), also integrated into the formula, contribute to maintaining normal triglyceride levels and support normal heart function.
In the Singular Formula
ApoB is a personalization parameter integrated into the Singular formulation engine. It reflects the number of circulating atherogenic particles, data directly usable for adjusting the cardiovascular component of the formula.
When ApoB falls in the high or very high zone, the formulation engine activates targeted cardiovascular support. The black garlic dosage is increased. This fermented extract concentrates organosulfur compounds (S-allyl-cysteine) and polyphenols evaluated for their influence on lipid profile.
The formula also includes omega-3 (EPA+DHA), which contribute to maintaining normal triglyceride levels and supporting normal heart function. Triglycerides and ApoB share common metabolic ground: hepatic VLDL overproduction increases the number of atherogenic particles.
ApoB is read alongside triglycerides and HDL cholesterol. This cross-reading distinguishes an isolated lipid profile from a broader metabolic profile.
Linked Bioactives
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Ference BA et al. | 2017 | Systematic Review | European Heart Journal | View on PubMed |
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Consensus statement synthesizing genetic, epidemiologic, and clinical evidence establishing that LDL causes atherosclerotic cardiovascular disease. Cumulative exposure to atherogenic lipoproteins over time is the determining factor. | ||||
| Sniderman AD et al. | 2019 | Systematic Review | JAMA Cardiology | View on PubMed |
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review Narrative review demonstrating that ApoB is a superior marker to LDL-C for assessing cardiovascular risk. Two individuals with identical LDL-C may present radically different particle profiles. | ||||
| Richardson TG et al. | 2020 | Cohort Study | PLoS Medicine | View on PubMed |
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis Multivariable Mendelian randomization analysis demonstrating that ApoB carries the causal relationship with coronary risk. The LDL-C association disappears after adjustment for ApoB. | ||||
| Glavinovic T et al. | 2022 | Systematic Review | Journal of the American Heart Association | View on PubMed |
Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk Analysis of the physiological bases for ApoB superiority: better arterial wall penetration of small dense particles, counting of all atherogenic lipoproteins, and lower intra-individual variability than LDL-C. | ||||
| Varvel SA et al. | 2015 | Cohort Study | Journal of Clinical Lipidology | View on PubMed |
Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice Clinical study showing that discordance between ApoB and LDL-C is associated with insulin resistance. Metabolic profiles with insulin resistance frequently present elevated ApoB despite normal LDL-C. | ||||
| Ference BA et al. | 2019 | Cohort Study | JAMA | View on PubMed |
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease Genetic analysis showing that cardiovascular risk reduction is proportional to ApoB decrease, regardless of the biological pathway (triglycerides via LPL or LDL-C via LDLR). | ||||
| Ference BA | 2018 | Systematic Review | Cardiology Clinics | View on PubMed |
Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies Review of genomic studies confirming the causal role of lipoproteins in atherosclerosis. ApoB is identified as the preferred marker in situations of frequent discordance. | ||||